Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cardiovascular drug development company Trigen has announced the completion of its first-in-man phase I study of platelet adhesion inhibitor PR-15.
Subscribe to our email newsletter
Dr Sophie Combe, VP of clinical development at Trigen, said: “Based on the promising results of this first-in-man study, investigation of PR-15 in patients is warranted to further evaluate its safety profile and potential efficacy in the management of arterial thrombosis.”
Trigen has likened the action of PR-15 to that of a ‘vascular sticking plaster’ due to its ability to prevent firm platelet adhesion to sites of arterial wall damage including ruptured atherosclerotic plaques. Such adhesion is the first step in platelet activation and aggregation leading to myocardial infarction (heart attack) and stroke and potentially stimulating further progression of atherosclerosis.
PR-15 is being developed as a novel agent to treat acute arterial thrombosis and prevent or retard progression of atherosclerosis.